Article thumbnail
Location of Repository

A dose-ranging study of tiotropium delivered via Respimat® Soft MistTM Inhaler or HandiHaler® in COPD patients

By Denis Caillaud, Charles Le Merre, Yan Martinat, Bernard Aguilaniu and Demetri Pavia

Abstract

This was a multicenter, randomized, double-blind within device, parallel-group, dose-ranging study. COPD patients (n = 202; 86% male; mean age: 61 years) were randomized to receive tiotropium 1.25 μg, 2.5 μg, 5 μg, 10 μg, or 20 μg Respimat® SMI (a novel, propellant-free device); tiotropium 18 μg HandiHaler®; placebo Respimat®; or placebo HandiHaler® for 3 weeks. The primary endpoint was trough FEV1 on Day 21. Other assessments included FVC, PEFR, rescue medication use, safety, and pharmacokinetics. In general, all active treatments improved the primary and secondary endpoints on Day 21 (steady state) compared with placebo. Tiotropium 5 μg Respimat®, 20 μg Respimat®, and tiotropium 18 μg HandiHaler® were statistically significantly higher than placebo for the primary endpoint (mean change in trough FEV1 was 150 mL (both Respimat® doses) versus 20 mL (placebo Respimat®); p < 0.05; and 230 mL (HandiHaler®) versus −90 mL (placebo HandiHaler®); p ≤ 0.001). The urinary excretion (up to 2 hours post-dose) of tiotropium 5–10 μg Respimat® was comparable with tiotropium 18 μg HandiHaler®; the overall incidence of adverse events was comparable across treatment groups. Tiotropium 5 and 10 μg Respimat® improve lung function in COPD patients and appear to be comparable with tiotropium 18 μg HandiHaler®

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2699972
Provided by: PubMed Central

Suggested articles

Citations

  1. (2002). A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J,
  2. (2004). A review of the development
  3. (2005). Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
  4. (2006). Confi rmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
  5. (2005). Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbohaler dry powder inhaler.
  6. (2004). Effects of tiotropium on lung hyperinfl ation, dyspnoea and exercise tolerance in COPD.
  7. (1996). Effi cient delivery to the lungs of fl unisolide aerosol from a new portable hand-held multidose nebulizer.
  8. (2003). Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
  9. (2004). Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. Respir Med,
  10. (2002). Improved health outcomes in patients with COPD during 1-year treatment with tiotropium. Eur Respir J,
  11. (2005). Improvements in symptomlimited exercise performance over 8 h with once-daily tiotropium in patients with COPD.
  12. (2006). Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Executive summary.
  13. (1998). Lung deposition of fenoterol and fl unisolide delivered using a novel device for inhaled medications.
  14. (1993). Lung volumes and forced ventilatory fl ows. Report Working Party Standardization of Lung Function Tests,
  15. (1999). Optimizing the in vitro performance of Respimat.
  16. (2000). Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
  17. (2005). Respimat Soft Mist Inhaler versus hydrofl uoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med,
  18. (2005). The role of tiotropium bromide, a long-acting anticholinergic bronchodilator, in the management of COPD. Treat Respir Med,
  19. (1995). Thoracic Society.
  20. (1995). Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD).
  21. (2005). Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther,
  22. (1999). Use of gamma scintigraphy to evaluate the performance of new inhalers.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.